Overactive Bladder - Results from #420

Oral Phenazopyridine vs Intravesical Lidocaine for Bladder OnabotulinumtoxinA Analgesia: A Randomized Controlled Trial (OPIL). May 22, 2022

Impact of Duration of Antibiotic Prophylaxis on Incidence of UTI after OnabotulinumtoxinA Injection. May 22, 2022

Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment. May 22, 2022

Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States. May 22, 2022

Adverse Events for Overactive Bladder Medications From a Public Federal Database. May 15, 2022

Health disparities and access to advanced therapy for overactive bladder. May 15, 2022

Assessing comprehension of online information in the United States for third-line treatment of overactive bladder. May 15, 2022

Combination and Novel Pharmacologic Agents for OAB. May 15, 2022

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations. May 8, 2022

Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children. May 8, 2022

Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review. May 8, 2022

Barriers and facilitators to overactive bladder therapy adherence. May 8, 2022

Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study. May 1, 2022

Advances in Assistive Electronic Device Solutions for Urology. May 1, 2022

Overactivity index: A noninvasive and objective outcome measure in overactive bladder in children. May 1, 2022

Efficacy of non-pharmacological interventions in females with overactive bladder: A systematic review and network meta-analysis. April 24, 2022

Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study. April 17, 2022

Utilization rate and long-term persistence of combination pharmacotherapy with β3-agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real-world setting. April 17, 2022

Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladder. April 17, 2022

The Prevalence of Lower Urinary Tract Symptoms and Overactive Bladder in South Korea: A Cross-Sectional, Population-Based Study. April 10, 2022

Page 22 of 122